en · de · es · fr · pt
aod-9604-notes.peptides6908.com › Blog › Background And Development History — Hands-On Walkthrough

Background And Development History — Hands-On Walkthrough

By Editorial Desk · published 2026-03-04 · last reviewed 2026-04-01 · Blog

The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Related pages on this site

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Notes from published material

An analysis of Global Burden of Disease Study data estimated that about 163 million people worldwide were living with a substance use disorder in 2021, comprising roughly 111 million cases of alcohol use disorder and about 53 million of drug use disorders. Although these totals rose as the world population grew, the age-standardized prevalence rate fell by about 17% between 1990 and 2021. Prevalence peaks in young adults, at roughly 25 to 29 years, and is consistently higher among males. Age-standardized prevalence was highest in high-income North America and lowest in western sub-Saharan Africa and in north Africa and the Middle East; rates fell in most regions, but drug use disorders rose in several high-income settings. Measured as a risk factor rather than as a disorder, alcohol use was responsible for an estimated 2.6 million deaths worldwide in 2019, or 4.7% of all deaths, and psychoactive drug use for a further 0.6 million; about 2 million of the alcohol-attributable and 0.4 million of the drug-attributable deaths were among men. Alcohol-attributable burden was heaviest in countries with a low Socio-demographic Index, whereas drug-attributable burden increased with higher socio-demographic development. Between 2010 and 2023, drug use was one of only three risk factors worldwide whose age-standardized attributable DALY rate rose.

== Relevance to human disease == Neuropeptides such as relaxin-3 are attracting increasing interest as targets for the pharmacological treatment of a range of neuropsychiatric diseases. Due to the ability of relaxin-3 to modulate neuronal processes/behaviours such as mood, stress responses and cognition, which are often aberrant in mental illnesses, considerable potential exists for the development of relaxin-3-based drugs to therapeutically treat depression and other mental illnesses.

The South African Defence Force (SADF) (Afrikaans: Suid-Afrikaanse Weermag) comprised the armed forces of South Africa from 1957 until 1994. Shortly before the state reconstituted itself as a republic in 1961, the former Union Defence Force was officially succeeded by the SADF, which was established by the Defence Act (No. 44) of 1957. The SADF, in turn, was superseded by the South African National Defence Force in 1994.

Sources: en.wikipedia.org

Further detail

Grannygate – scandal in March 2000 over the eligibility of Shane Howarth and Brett Sinkinson representing the Wales national team Kamp Staaldraad – controversial training camp for the Springboks (South Africa's national rugby union team) before the 2003 Rugby World Cup "Bloodgate" – a scheme by the English rugby union club Harlequins to fake an injury to wing Tom Williams to allow a blood replacement to be brought on at a critical moment in their 2009 Heineken Cup quarterfinal against Leinster. The scheme, which included deliberately cutting Williams' mouth open after the match in order to cover up the fake injury, ultimately led to Quins head coach Dean Richards being banned from the sport for three years.

=== Illegal gambling groups === Jogo do bicho (Animal game) is an illegal gambling game in Brazil, which is still incredibly popular and sought out despite its federal prohibition in 1946. The game is played all around the country, with lottery-style drawings in every state occurring daily in its headquarters in Greater Rio de Janeiro. The game is controlled by bosses, called bicheiros or banqueiros ("bankers"). Jogo do Bicho is a longstanding staple in Brazilian culture, with thousands participating in the game daily. Because of its potential to circulate and raise large sums of money, control of Jogo do Bicho is lucrative and largely contributes to corruption, with politicians, judicial personnel, and members of the police force all monetarily and politically benefitting from it. Bicheiros also contribute funding to social programs, such as samba schools, which play a critical role in cultural festivities such as Brazilian Carnival. Because of this, Jogo do Bicho, and in turn its bicheiros, are deeply ingrained in Brazilian culture, especially in Rio de Janeiro, and contribute to the landscape of organized crime and corruption.

=== Direct reaction of metal with carbon monoxide === Nickel tetracarbonyl and iron pentacarbonyl can be prepared according to the following equations by reaction of finely divided metal with carbon monoxide:

Ecotutu limited is a Nigeria-based company that provides solar-powered cold storage for large and small-scale farmers. Ecotutu is amongst the major companies in Nigeria in agriculture/food and health cold value chain.

Sources: en.wikipedia.org

Background from the literature

There is a wide variety in the mechanical properties achievable in biosynthetic spider silk depending on the spidroin sequences used, spinning method, native spider species and whether efficiency in production or maximum mechanical properties are emphasized.

Using only the egg yolk. Using specialized devices to whip the egg, particularly the egg white into a meringue-like foam before pouring over the rice. A cooking toy called the Kyūkyoku no TKG (Ultimate TKG) was marketed by Takara Tomy Arts in 2017 specifically for this purpose.

===== Neuraminidase (NA) removal of sialic acid ===== Neuraminidase (NA) removal of cytotoxic T lymphocytes from the surface of malignant cells stimulates natural killer cells and cytotoxic T lymphocytes. Increased sialylation levels on the cell membrane have been linked to a heightened potential for invasion and metastasis in cancer cells. This correlation has been observed across various models, including murine, rat, and human, and is associated with the progression of malignancy. Some sialylation inhibitors can make cancer cells less malignant. One possible explanation for the relationship between increased sialylation and a malignant phenotype is that sialylation results in a thick layer of coating on the cell membrane that masks cancer antigens and protects malignant cells from immune surveillance. The activity and cytotoxicity of NK cells is inhibited by the expression of sialic acids on the tumor cell surface. Removal of sialic acid residues from the surface of tumor cells makes them available to NK cells and cytotoxic T lymphocytes and, therefore, reduces their growth potential. Moreover, treating tumor cells with sialidase improves activation of NK cell secretion of IFN-γ. Some paramyxoviruses, including SeV encode and synthesize neuraminidase (sialidase), which can remove sialic acid residues from the surface of malignant cells. Hemagglutinin-neuraminidase (HN) is a single protein that induces hemagglutination and possesses neuraminidase (sialidase) activity. Neuraminidase (NA), a subunit of the HN protein, binds to and cleaves sialic acid from the cell surface.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

Network